BHST — BioHarvest Sciences Inc. Common Stock

Summary of BioHarvest Sciences Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased 39% year-over-year to $9.1 million, meeting guidance.
• Product Revenue: Grew 30% to $8.4 million; CDMO revenue surged 722% to $0.7 million.
• Gross Profit: Rose 50% to $5.6 million, with a gross margin of 61%, up from 57% in Q3 2024.
• Operating Expenses: Totaled $6.5 million, up from $5.8 million, primarily due to increased marketing and CDMO expenses.
• Net Loss: $2.5 million ($0.14 per share), slightly improved from a loss of $2.7 million ($0.16 per share) in Q3 2024.
• Adjusted EBITDA: Loss narrowed to $0.4 million from $1.7 million year-over-year.
• Cash Position: $11 million as of September 30, 2025, significantly improved from $2.4 million at year-end 2024.

2. Strategic Updates and Business Highlights

• VINIA Product Growth: Active user base surpassed 75,000; strong performance from core VINIA capsules and new product launches, including VINIA 2X Formula Chews.
• CDMO Partnerships: Secured a new partnership with Saffron Tech to develop saffron-derived compounds, with BioHarvest retaining a 25% ownership stake.
• Health Pros Program: Launched Phase 1 of the VINIA Health Pros professional affiliate program, onboarding 75 health professionals with a target of 300 by year-end.
• New Product Launch: VINIA BloodFlow Hydration Solution set for broader launch on December 3, 2025, with positive early feedback from VIP users.

3. Forward Guidance and Outlook

• Q4 2025 Expectations: Anticipated revenue between $9 million to $9.5 million; adjusted EBITDA projected to be near breakeven.
• Long-term Goals: Aiming for adjusted EBITDA breakeven by early 2026, with plans to triple manufacturing capacity and expand CDMO services.

4. Bad News, Challenges, or Points of Concern

• Operating Expenses: Increased spending on marketing and program development may pressure profitability in the short term.
• Market Competition: Entering a highly competitive $17 billion electrolyte hydration market, with established players like Liquid I.V. posing significant challenges.
• Execution Risks: Reliance on successful product launches and scaling of new initiatives like the Health Pros program could impact future revenue if not executed effectively.

5. Notable Q&A Insights

• Hydration Product Ramp-Up: CEO Ilan Sobel indicated a staged launch for the hydration product, with expectations for gradual revenue growth starting in December and into Q1 2026.
• CDMO Business Potential: Sobel highlighted a robust pipeline for CDMO partnerships, projecting that this segment could account for 75% of revenue in 5-7 years, with margins exceeding 70%.
• Health Pros Program: Positive early results from the Health Pros program suggest effective customer acquisition at lower costs, with plans to scale rapidly.
• Exosome Technology: Ongoing development in exosome technology is expected to enhance the value proposition for CDMO customers, potentially leading to more lucrative deals.

This summary encapsulates the key elements discussed during the earnings call, providing a clear overview of BioHarvest Sciences' current performance and future outlook.